Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections
- PMID: 39324801
- PMCID: PMC11539207
- DOI: 10.1128/aac.00752-24
Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections
Abstract
Obesity affects over one-third of U.S. adults and complicates the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSI). A study at the University of Florida Health Centers compared clinical outcomes between 233 obese and non-obese patients receiving cefazolin for MSSA BSI. No significant differences were found in clinical success (81.9% vs 82.7%), mortality (7.2% vs 5.3%), or adverse events (3.6% vs 3.3%). However, obese patients took longer to clear blood cultures (4.62 vs 4.01 days, P = 0.017).
Keywords: cefazolin; methicillin-susceptible Staphylococcus aureus; obesity.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- CDC . 2022. Obesity is a common, serious, and costly disease. Available from: https://www.cdc.gov/obesity/data/adult.html. Retrieved 23 Apr 2024.
-
- Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. International Journal of Obesity. Available from: https://www.nature.com/articles/s41366-021-01035-6. Retrieved 23 Apr 2024. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
